TABLE 5.
Cox Regression for the Association Between Race, and OS, Adjusted for Potential Confounders Determined A Priori
| Univariable | Multivariable | |||
|---|---|---|---|---|
| Parameter | HR (95% CI) | p-value | HR (95% CI) | p-value |
| White race | 0.51 (0.35-0.74) | <0.001 | 0.79 (0.43, 1.45) | 0.443 |
| Mode of diagnosis | <0.001 | -- | -- | |
| Mammogram | 1.00 | |||
| Other | 0.18 (0.02-1.5) | |||
| Physical findings | 4.18 (1.93-9.03) | |||
| Insurance | 0.31 | -- | -- | |
| Government | 1.00 | |||
| Commercial/Private | 1.43 (0.72-2.83) | |||
| Tumor size (cm) | 1.47 (1.17-1.85) | 0.001 | 1.46 (0.93, 2.31) | 0.102 |
| AJCC Stage | <0.001 | 0.247 | ||
| Stage I | 1.00 | 1.00 | ||
| Stage II | 1.97 (1.07-3.64) | 0.69 (0.18, 2.68) | ||
| Stage III | 7.69 (3-19.68) | 2.12 (0.28, 16.26) | ||
| ER+ | 0.31 (0.16-0.59) | <0.001 | -- | -- |
| PR+ | 0.54 (0.32-0.9) | 0.018 | -- | -- |
| HER2+ | 0.67 (0.3-1.48) | 0.321 | -- | -- |
| Grade (Histological) | 0.118 | -- | -- | |
| 1 | 1.00 | |||
| 2 | 1.63 (0.37-7.16) | |||
| 3 | 2.82 (0.74-10.68) | |||
| Nodal positivity | 2.71 (1.55-4.72) | <0.001 | 1.35 (0.37, 4.87) | 0.651 |
| ECE | 2.73 (1.37-5.44) | 0.004 | 1.41 (0.35, 5.75) | 0.633 |
| LVI | 2.64 (1.43-4.89) | 0.002 | 1.02 (0.31, 3.3) | 0.974 |
| Molecular subtype | 0.009 | 0.196 | ||
| HR+/HER2− | 1.00 | 1.00 | ||
| HR−/HER2+ | 1.05 (0.27-4.02) | 0.5 (0.06, 3.89) | ||
| HR−/HER2− | 3.42 (1.66-7.06) | 3.88 (1.32, 11.46) | ||
| HR+/HER2+ | 1.03 (0.37-2.89) | 0.53 (0.11, 2.45) | ||
| Mastectomy vs BCS | 2.05 (1.19-3.55) | 0.001 | 1.80 (0.73, 4.48) | 0.205 |
| Chemotherapy | 2.38 (1.25-4.56) | 0.009 | 1.98 (0.61, 6.41) | 0.253 |
Abbreviations: OS, overall survival; HR, hazard ratio; CI, confidence interval; AJCC, American Joint Committee on Cancer; ER, estrogen receptor, ECE, extracapsular extension; LVI, lymphovascular invasion; BCS, breast-conserving surgery